Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
This study is ongoing, but not recruiting participants.
Study NCT01503502 Information provided by Jiangsu HengRui Medicine Co., Ltd.
First Received on January 1, 2012. Last Updated on April 9, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Myelogenous Leukemia, Chronic
Additional conditions recognized in this trial
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
More general conditions related to this trial
Bone Marrow Diseases
Neoplasms by Histologic Type
Interventions listed in this trial
More general drug interventions related to this trial
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors
Sponsors listed in this trial
Jiangsu HengRui Medicine Co., Ltd.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers